MEMPHIS, Tenn. (AP) — Biopharmaceutical company GTx Inc. said Wednesday the Food and Drug Administration is reviewing its application for the drug candidate toremifene. In December, the company filed an application with the regulatory agency to approve toremifene for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy. GTx said it expects more guidance in the coming weeks on the FDA’s timeline for the review. Prostate cancer is the second most common type of cancer diagnosed in men in the U.S. An estimated 186,000 new cases of prostate cancer were diagnosed in the U.S. in 2008. Androgen deprivation therapy, which treats the cancer, tends to weaken bones.